Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats.

Journal of Neurochemistry
Mei LiuGuoying Bing

Abstract

Trichloroethylene, a chlorinated solvent widely used as a degreasing agent, is a common environmental contaminant. Emerging evidence suggests that chronic exposure to trichloroethylene may contribute to the development of Parkinson's disease. The purpose of this study was to determine if selective loss of nigrostriatal dopaminergic neurons could be reproduced by systemic exposure of adult Fisher 344 rats to trichloroethylene. In our experiments, oral administration of trichloroethylene induced a significant loss of dopaminergic neurons in the substantia nigra pars compacta in a dose-dependent manner, whereas the number of both cholinergic and GABAergic neurons were not decreased in the striatum. There was a robust decline in striatal levels of 3, 4-dihydroxyphenylacetic acid without a significant depletion of striatal dopamine. Rats treated with trichloroethylene showed defects in rotarod behavior test. We also found a significantly reduced mitochondrial complex I activity with elevated oxidative stress markers and activated microglia in the nigral area. In addition, we observed intracellular alpha-synuclein accumulation in the dorsal motor nucleus of the vagus nerve, with some in nigral neurons, but little in neurons of cerebr...Continue Reading

References

Feb 1, 1991·British Journal of Industrial Medicine·M W RuijtenH J Sallé
Jan 1, 1994·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·W WesemannP Riederer
Dec 1, 1994·Annals of Neurology·V M MannA H Schapira
Mar 1, 1993·Acta Neurologica Scandinavica·K RasmussenS Sabroe
Jan 23, 1998·Brain Research. Brain Research Protocols·G RozasJ L Labandeira-García
Aug 27, 1998·Journal of Cancer Research and Clinical Oncology·S VamvakasK Ulm
Aug 24, 1999·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·D GuehlC Gross
May 12, 2000·Environmental Health Perspectives·L H LashJ C Parker
May 12, 2000·Environmental Health Perspectives·C S Scott, V J Cogliano
Aug 22, 2001·Lancet·R W Jones
Dec 4, 2002·Nature Reviews. Neuroscience·Julie Lotharius, Patrik Brundin
Dec 25, 2002·Neurobiology of Aging·Heiko BraakEva Braak
Jun 5, 2003·Annals of Neurology·Patrick G SullivanTallie Z Baram
Sep 25, 2003·Biochemical Society Transactions·D M F Cooper
Nov 1, 2003·Science·Ted M Dawson, Valina L Dawson
Aug 7, 2004·Industrial Health·Sompis PantucharoensriSomchai Prasartsansoui
Aug 10, 2004·Nature Medicine·Julie K Andersen
Sep 21, 2004·Journal of Bioenergetics and Biomembranes·Maile R BrownPatrick G Sullivan
May 23, 2006·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Gerhard BringmannWolfgang Wesemann
Jul 7, 2006·Cellular and Molecular Neurobiology·Toshi Nagatsu, Makoto Sawada
Sep 13, 2006·Environmental Health Perspectives·Weihsueh A ChiuCheryl Siegel Scott
Mar 7, 2007·British Journal of Pharmacology·P S Whitton
Dec 25, 2007·Annals of Neurology·Don M GashT Scott Prince

❮ Previous
Next ❯

Citations

May 12, 2011·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Paul M A AntonyRudi Balling
May 11, 2011·Antioxidants & Redox Signaling·Terina N Martinez, J Timothy Greenamyre
Sep 15, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·Jason R Cannon, J Timothy Greenamyre
Dec 5, 2013·Neuroscience and Biobehavioral Reviews·Fares Zeidán-ChuliáJosé Cláudio Fonseca Moreira
Sep 21, 2013·Annual Review of Pharmacology and Toxicology·Samuel M Goldman
Jul 11, 2012·Neurobiology of Disease·Jason R Cannon, J Timothy Greenamyre
Feb 9, 2012·Neurotoxicology·W Michael CaudleGary W Miller
Aug 2, 2011·Neurologic Clinics·Fariha Zaheer, John T Slevin
Jun 16, 2011·Neurochemistry International·Eun-Joo ShinHyoung-Chun Kim
Nov 16, 2011·Annals of Neurology·Samuel M GoldmanCaroline M Tanner
Dec 20, 2011·Experimental Neurology·Daniel R van BregtJonathan Lifshitz
Apr 29, 2015·Frontiers in Cellular Neuroscience·Miguel Chin-ChanBetzabet Quintanilla-Vega
Jan 13, 2015·Parkinsonism & Related Disorders·Oliver PalinCarl E Clarke
May 12, 2016·Regulatory Toxicology and Pharmacology : RTP·Noriyuki OtsukiJunichi Fujii
Oct 7, 2016·International Journal of Epidemiology·Douglas I WalkerQing Lan
Nov 14, 2016·Revue neurologique·J ReisP S Spencer
Apr 6, 2013·International Journal of Toxicology·Catherine McDermott, James J A Heffron
Dec 23, 2017·Molecular Neurobiology·Mei LiuHyoung-Chun Kim
Feb 22, 2018·Reviews in the Neurosciences·Sarita SinghPrahlad Kishore Seth
Jun 4, 2010·Expert Review of Neurotherapeutics·Samuel M Goldman
Jan 31, 2020·Environmental Science. Processes & Impacts·Briana R De Miranda, J Timothy Greenamyre
Nov 21, 2017·Acta Neuropathologica·Peizhou Jiang, Dennis W Dickson
Oct 11, 2017·Toxicology Research·Jessica H HartmanJoel N Meyer
Jul 11, 2020·Biomedicines·Lisa M BarnhillJeff M Bronstein
Oct 1, 2020·Environmental Science and Pollution Research International·Supriya SharmaFaheem Hyder Pottoo
May 16, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Connie MarrasSamuel M Goldman
Mar 26, 2021·Neurotoxicity Research·Mohamed El-GamalAhmed A Moustafa
Jul 22, 2021·Archives of Pharmacal Research·Eun-Joo ShinHyoung-Chun Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.